Literature DB >> 29178427

CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells.

Ilaria Schiavoni1, Carolina Scagnolari2, Alberto L Horenstein3,4, Pasqualina Leone1, Alessandra Pierangeli2, Fabio Malavasi3,4,5, Clara M Ausiello1, Giorgio Fedele1.   

Abstract

Respiratory syncytial virus (RSV) is the most common cause of hospitalization due to bronchiolitis in infants. Although the mechanisms behind this association are not completely elucidated, they appear to involve an excessive immune response causing lung pathology. Understanding the host response to RSV infection may help in the identification of targets for therapeutic intervention. We infected in-vitro human monocyte-derived dendritic cells (DCs) with RSV and analysed various aspects of the cellular response. We found that RSV induces in DCs the expression of CD38, an ectoenzyme that catalyses the synthesis of cyclic ADPR (cADPR). Remarkably, CD38 was under the transcriptional control of RSV-induced type I interferon (IFN). CD38 and a set of IFN-stimulated genes (ISGs) were inhibited by the anti-oxidant N-acetyl cysteine. When CD38-generated cADPR was restrained by 8-Br-cADPR or kuromanin, a flavonoid known to inhibit CD38 enzymatic activity, RSV-induced type I/III IFNs and ISGs were markedly reduced. Taken together, these results suggest a key role of CD38 in the regulation of anti-viral responses. Inhibition of CD38 enzymatic activity may represent an encouraging approach to reduce RSV-induced hyperinflammation and a novel therapeutic option to treat bronchiolitis.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  inflammation; interferons; monocyte-derived dendritic cells; respiratory syncytial virus

Mesh:

Substances:

Year:  2017        PMID: 29178427      PMCID: PMC5904717          DOI: 10.1111/imm.12873

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Authors:  T Vaisitti; V Audrito; S Serra; R Buonincontri; G Sociali; E Mannino; A Pagnani; A Zucchetto; E Tissino; C Vitale; M Coscia; C Usai; C Pepper; V Gattei; S Bruzzone; S Deaglio
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

2.  Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.

Authors:  Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio
Journal:  Pediatrics       Date:  2014-11       Impact factor: 7.124

3.  Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II.

Authors:  B Bauvois; L Durant; J Laboureau; E Barthélémy; D Rouillard; G Boulla; P Deterre
Journal:  J Interferon Cytokine Res       Date:  1999-09       Impact factor: 2.607

4.  Flavonoids as inhibitors of human CD38.

Authors:  Esther Kellenberger; Isabelle Kuhn; Francis Schuber; Hélène Muller-Steffner
Journal:  Bioorg Med Chem Lett       Date:  2011-05-14       Impact factor: 2.823

Review 5.  Respiratory syncytial virus infection and immunity.

Authors:  Pablo A González; Susan M Bueno; Leandro J Carreño; Claudia A Riedel; Alexis M Kalergis
Journal:  Rev Med Virol       Date:  2012-01-31       Impact factor: 6.989

Review 6.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.

Authors:  Silvia Deaglio; Simon C Robson
Journal:  Adv Pharmacol       Date:  2011

Review 7.  Innate immune responses to respiratory syncytial virus infection.

Authors:  Sumanta Mukherjee; Nicholas W Lukacs
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

8.  Synthesis and characterization of antagonists of cyclic-ADP-ribose-induced Ca2+ release.

Authors:  T F Walseth; H C Lee
Journal:  Biochim Biophys Acta       Date:  1993-09-13

9.  Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo.

Authors:  Nancy A Jewell; Negin Vaghefi; Sara E Mertz; Parvis Akter; R Stokes Peebles; Lauren O Bakaletz; Russell K Durbin; Emilio Flaño; Joan E Durbin
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

10.  Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome.

Authors:  Carlos Escande; Veronica Nin; Nathan L Price; Verena Capellini; Ana P Gomes; Maria Thereza Barbosa; Luke O'Neil; Thomas A White; David A Sinclair; Eduardo N Chini
Journal:  Diabetes       Date:  2012-11-19       Impact factor: 9.461

View more
  18 in total

Review 1.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

2.  CD38 Enhances TLR9 Expression and Activates NLRP3 Inflammasome after Porcine Parvovirus Infection.

Authors:  Yi Zheng; Yixuan Xu; Weimin Xu; Sanjie Cao; Qigui Yan; Xiaobo Huang; Yiping Wen; Qin Zhao; Senyan Du; Yifei Lang; Shan Zhao; Rui Wu
Journal:  Viruses       Date:  2022-05-25       Impact factor: 5.818

Review 3.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 4.  Role of CD38/cADPR signaling in obstructive pulmonary diseases.

Authors:  Alonso Gp Guedes; Mythili Dileepan; Joseph A Jude; Deepak A Deshpande; Timothy F Walseth; Mathur S Kannan
Journal:  Curr Opin Pharmacol       Date:  2020-05-29       Impact factor: 5.547

Review 5.  The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging.

Authors:  Eduardo N Chini; Claudia C S Chini; Jair Machado Espindola Netto; Guilherme C de Oliveira; Wim van Schooten
Journal:  Trends Pharmacol Sci       Date:  2018-02-23       Impact factor: 14.819

Review 6.  CD38: A Potential Therapeutic Target in Cardiovascular Disease.

Authors:  Wanyun Zuo; Na Liu; Yunhong Zeng; Yaozhong Liu; Biao Li; Keke Wu; Yunbin Xiao; Qiming Liu
Journal:  Cardiovasc Drugs Ther       Date:  2021-08       Impact factor: 3.727

Review 7.  CD38/cADPR Signaling Pathway in Airway Disease: Regulatory Mechanisms.

Authors:  Deepak A Deshpande; Alonso G P Guedes; Richard Graeff; Soner Dogan; Subbaya Subramanian; Timothy F Walseth; Mathur S Kannan
Journal:  Mediators Inflamm       Date:  2018-02-07       Impact factor: 4.711

Review 8.  The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases.

Authors:  Kelly A Hogan; Claudia C S Chini; Eduardo N Chini
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 8.786

Review 9.  Immune-Modulation by the Human Respiratory Syncytial Virus: Focus on Dendritic Cells.

Authors:  Eduardo I Tognarelli; Susan M Bueno; Pablo A González
Journal:  Front Immunol       Date:  2019-04-15       Impact factor: 7.561

Review 10.  Roles of CD38 in the Immune Response to Infection.

Authors:  Estibaliz Glaría; Annabel F Valledor
Journal:  Cells       Date:  2020-01-16       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.